article thumbnail

Certain menopausal hormone therapy could raise ovarian cancer risk, study finds

Bio Pharma Dive

The findings, from two trials involving tens of thousands of women, could influence guidelines around the use of hormonal treatment for menopausal symptoms.

Hormones 280
article thumbnail

New male contraceptive does not involve hormones

Medical Xpress

Instead of using hormones to disrupt sperm production, the new technique involves placing a hydrogel called ADAM into the vas deferens to prevent sperm from making its way to the urethra.

Hormones 143
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Ibutamoren mesylate by Lumos Pharma for Growth Hormone Deficiency: Likelihood of Approval

Pharmaceutical Technology

Ibutamoren mesylate is under clinical development by Lumos Pharma and currently in Phase II for Growth Hormone Deficiency. According to GlobalData, Phase II drugs for Growth Hormone Deficiency have a 63% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. It is administered orally.

Hormones 100
article thumbnail

Camurus Shares Positive Phase III Results from Acromegaly Trial

XTalks

Sweden-based biotech Camurus shared positive Phase III trial data for CAM2029, one of its lead candidates, in patients with the rare hormonal disorder acromegaly. Due to its ability to mimic somatostatin, octreotide is used to treat various conditions associated with excessive hormone production.

Trials 59
article thumbnail

Bayer eyes Nubeqa’s label expansion in prostate cancer following Phase III win

Pharmaceutical Technology

The Phase III trial evaluating Nubeqa in patients with metastatic hormone-sensitive prostate cancer met its primary endpoint.

Hormones 130
article thumbnail

Pfizer’s Ngenla Approved as Once-Weekly Treatment for Pediatric Growth Hormone Deficiency (GHD)

XTalks

Pfizer has been going strong on the approval front, having secured its fifth US Food and Drug Administration (FDA) approval in the past five weeks, with the most recent being for the company’s once-weekly human growth hormone analog Ngenla (somatrogon-ghla).

article thumbnail

Bayer’s Nubeqa, en route to blockbusterland, clinches 2nd win in prostate cancer subtype

Fierce Pharma

Bayer has claimed a second pivotal trial win for its blockbuster-to-be androgen receptor inhibitor Nubeqa, looking to reach the entire space of metastatic hormone-sensitive prostate cancer (mHSPC).